Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shannon Pope

Internal Medicine Smithfield, VA Medical Doctor

NPI 1558342733 CMS profile 116026

201 Gumwood Dr, Smithfield, VA 23430

Open in the dashboard

General payments

$6,760

392 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Pope of Smithfield, VA is reported in the CMS Open Payments database as having received $6,760 across 392 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $858 40
2024 General $1,147 52
2023 General $1,045 68
2022 General $817 52
2021 General $1,041 53
2020 General $771 49
2019 General $1,081 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Pope
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shannon Pope were reported at $858. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shannon Pope Internal Medicine median Middle half National median
2019 $1,081 $159 $48–$570 $163
2020 $771 $119 $33–$402 $114
2021 $1,041 $135 $37–$521 $132
2022 $817 $141 $42–$496 $149
2023 $1,045 $149 $45–$519 $160
2024 $1,147 $154 $47–$537 $164
2025 $858 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,653 108 payments
  2. AstraZeneca Pharmaceuticals LP $1,094 45 payments
  3. Lilly USA, LLC $518 35 payments
  4. AbbVie, Inc. $404 28 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $367 25 payments
  6. Merck Sharp & Dohme Corporation $329 25 payments
  7. Janssen Pharmaceuticals, Inc $301 18 payments
  8. Astellas Pharma US Inc $219 7 payments
  9. Pfizer Inc. $179 11 payments
  10. GlaxoSmithKline, LLC. $171 10 payments
  11. Other $1,526 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,611 390 payments
  2. Education $149 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $929 69 payments
  2. FARXIGA $767 25 payments
  3. RYBELSUS $635 44 payments
  4. Wegovy $438 18 payments
  5. XIFAXAN $367 25 payments
  6. BREZTRI $302 10 payments
  7. XARELTO $301 18 payments
  8. STEGLATRO $267 19 payments
  9. JARDIANCE $242 16 payments
  10. TRULICITY $235 17 payments
  11. Other $4,964 306 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,211

Median for Internal Medicine: 777

Drug cost

$226,462

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 34 $67,274
Mounjaro Tirzepatide Brand 41 $55,465
Eliquis Apixaban Brand 20 $20,674
Xarelto Rivaroxaban Brand 18 $20,177
Jardiance Empagliflozin Brand 12 $18,977
Farxiga Dapagliflozin Propanediol Brand 12 $9,217
Dulera Mometasone/Formoterol Brand 17 $6,735
Synthroid Levothyroxine Sodium Brand 73 $2,406
Atorvastatin Calcium Generic 225 $2,117
Rosuvastatin Calcium Generic 143 $1,861

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$102,449

Of which drugs: $19,730

Medicare patients

392

Average age 75

Services billed

2,152

251 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 33%
Ischemic heart disease 21%
Depression 19%
Cancer 15%
Atrial fibrillation 13%
Heart failure 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 44 52 $7,976
Vaccine for influenza for injection into muscle 90662 Office 78 80 $6,148
Pcv20 vaccine im 90677 Office 18 18 $5,193

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $248
$248 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $96
$96 12 —
Ozempic
  • Novo Nordisk Inc $86
$86 34 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —
ZEPBOUND
  • Lilly USA, LLC $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record